FDA has released updated guidance detailing its plans to streamline authorization of COVID-19 vaccines adapted to more-infectious variants, such as the U.K. variant B.1.1.7, which is now present in dozens of states. FDA’s guidance would require such companies to launch small clinical studies similar to those needed for annual flu vaccines. It also encourages sponsors…